

IP8 DEPRESSION THERAPEUTICS PRACTICE TEST (SAMPLE)

STUDY GUIDE



SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR
THE FULL VERSION STUDY GUIDE

<https://ip8depressiontherapeutics.examzify.com>



Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.

SAMPLE

Table of Contents

Copyright	1
Table of Contents	2
Introduction	3
How to Use This Guide	4
Questions	5
Answers	8
Explanations	10
Next Steps	15

SAMPLE

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

Questions

SAMPLE

- 1. If there is a response (>50% symptom improvement) after 4-8 weeks of first-line antidepressant therapy, what is the recommended next step?**
 - A. Discontinue therapy
 - B. Maintain treatment for 6-12 months
 - C. Switch to another class
 - D. Increase the dose further

- 2. Which statement best describes augmentation strategies for treatment-resistant depression?**
 - A. They can provide greater response but increase risk of metabolic side effects.
 - B. They always have fewer side effects than antidepressants alone.
 - C. They are never used in combination.
 - D. They cure depression.

- 3. Which augmentation strategy to SSRI has the strongest evidence for improving outcomes in treatment-resistant depression?**
 - A. Lithium
 - B. Second-generation antipsychotics
 - C. Stimulants
 - D. Buspirone

- 4. Which antidepressant class is associated with potential weight loss and may be preferred in overweight patients?**
 - A. Sertraline; weight gain
 - B. Mirtazapine; weight gain
 - C. Paroxetine; weight gain
 - D. Bupropion; weight-neutral to weight loss; may help with energy and concentration

- 5. How is treatment-resistant depression (TRD) defined in pharmacotherapy?**
 - A. Failure to respond to at least two adequate trials of antidepressants from different classes, given at adequate doses and durations.
 - B. Nonresponse after one week
 - C. Nonresponse to psychotherapy only
 - D. Response to placebo therapy

- 6. What is a common gastrointestinal side effect of sertraline?**
- A. Constipation more common
 - B. Diarrhea is more common
 - C. Nausea never occurs
 - D. No GI effects
- 7. For pediatric antidepressant follow-up, how often should follow-up occur during the first four weeks after starting an antidepressant?**
- A. Daily
 - B. Weekly
 - C. Biweekly
 - D. Monthly
- 8. What is the next treatment option after suboptimal response (<20% symptom improvement) or intolerance following 4-8 weeks of first-line antidepressant therapy?**
- A. Switch to an alternative antidepressant in the same or different class (SSRI, SNRI, bupropion, or mirtazapine) ± psychotherapy
 - B. Discontinue treatment and consider non-pharmacologic therapy
 - C. Augment with a 2nd-generation antipsychotic
 - D. Maintain the current treatment and reassess in 2-4 weeks
- 9. Which of the following is not a DSM-5 symptom criterion for major depressive disorder?**
- A. Depressed mood.
 - B. Insomnia.
 - C. Psychomotor agitation.
 - D. Euphoria.
- 10. Which of the following is NOT a symptom of antidepressant withdrawal syndrome?**
- A. Flu-like symptoms
 - B. Insomnia
 - C. Nausea
 - D. Weight gain

Answers

SAMPLE

1. B
2. A
3. B
4. D
5. A
6. B
7. B
8. A
9. D
10. D

SAMPLE

Explanations

SAMPLE

1. If there is a response (>50% symptom improvement) after 4-8 weeks of first-line antidepressant therapy, what is the recommended next step?

- A. Discontinue therapy
- B. Maintain treatment for 6-12 months**
- C. Switch to another class
- D. Increase the dose further

When a patient shows a meaningful response to a first-line antidepressant—about a 50% reduction in symptoms—the next step is to continue the same treatment for 6 to 12 months. This continuation period helps solidify the improvement and reduces the risk of relapse once symptoms have improved. If the person has multiple depressive episodes or other relapse risk factors, longer maintenance (even beyond a year) may be considered. Discontinuing the medication right after a response increases relapse risk. Increasing the dose isn't usually needed when there's a clear response, and switching to another class is typically reserved for cases of incomplete response or intolerance.

2. Which statement best describes augmentation strategies for treatment-resistant depression?

- A. They can provide greater response but increase risk of metabolic side effects.**
- B. They always have fewer side effects than antidepressants alone.
- C. They are never used in combination.
- D. They cure depression.

Augmentation strategies involve adding another medication to an antidepressant when the response is incomplete. This approach can produce a greater antidepressant response for many patients with treatment-resistant depression. But introducing another drug often brings additional side effects, and some augmentation options are notably associated with metabolic changes such as weight gain, dyslipidemia, and insulin resistance. Those metabolic risks are a key consideration when choosing an augmentation agent, so the possibility of a higher metabolic side-effect burden accompanies the potential for improved efficacy. The other statements are inaccurate: augmentation is not guaranteed to have fewer side effects, it is used in combination, and it does not cure depression in most cases.

3. Which augmentation strategy to SSRI has the strongest evidence for improving outcomes in treatment-resistant depression?

- A. Lithium
- B. Second-generation antipsychotics**
- C. Stimulants
- D. Buspirone

Adding a second-generation antipsychotic to an SSRI has the strongest evidence for improving outcomes in treatment-resistant depression. Across multiple randomized trials and meta-analyses, these agents—notably aripiprazole and quetiapine XR—consistently improve both response and remission rates when used as augmentation after SSRI failure. Their robust efficacy is reflected in repeated positive findings and FDA approvals for this use, making them the most well-supported augmentation option in this scenario. While lithium augmentation has a long history of efficacy, the aggregate evidence for SGAs is stronger and more consistently demonstrated across diverse studies. Stimulants and buspirone have more variable results and less compelling overall data in this specific setting. Safety considerations—such as metabolic effects, weight gain, sedation, extrapyramidal symptoms, and prolactin elevation—should be discussed and monitored, but the efficacy signal for SGAs remains the strongest.

4. Which antidepressant class is associated with potential weight loss and may be preferred in overweight patients?

- A. Sertraline; weight gain
- B. Mirtazapine; weight gain
- C. Paroxetine; weight gain
- D. Bupropion; weight-neutral to weight loss; may help with energy and concentration**

Weight effects vary a lot across antidepressants, and in overweight patients the goal is to avoid adding weight. Bupropion stands out because it works by increasing norepinephrine and dopamine in the brain, which tends to boost energy and can suppress appetite. This combination often leads to weight neutrality or even weight loss, rather than weight gain, and it also can improve energy and concentration. That's why it's considered a preferred option when weight management is a concern. Other commonly used antidepressants in this context are more likely to be associated with weight gain or sedation, which makes them less favorable for someone worried about weight. Of course, bupropion has its own cautions, such as the risk of seizures in certain individuals and potential sleep or anxiety effects, so it's chosen based on a comprehensive patient picture.

5. How is treatment-resistant depression (TRD) defined in pharmacotherapy?

- A. Failure to respond to at least two adequate trials of antidepressants from different classes, given at adequate doses and durations.**
- B. Nonresponse after one week
- C. Nonresponse to psychotherapy only
- D. Response to placebo therapy

TRD in pharmacotherapy means not achieving a meaningful improvement after at least two adequate antidepressant trials, each given at a therapeutic dose for an adequate duration, and ideally from different drug classes. This setup ensures the failure isn't due to using too low a dose, too short a trial, or trying only one mechanism. In practice, an adequate duration is typically about 4 to 8 weeks per trial, with doses within the approved therapeutic range and confirmed adherence. Also note that nonresponse after one week is not enough to label TRD, and nonresponse to psychotherapy alone or a response to placebo does not define pharmacotherapy TRD.

6. What is a common gastrointestinal side effect of sertraline?

- A. Constipation more common
- B. Diarrhea is more common**
- C. Nausea never occurs
- D. No GI effects

Sertraline can cause gastrointestinal upset because serotonin in the gut regulates intestinal movement. Increasing serotonin levels with this medication tends to speed up gut motility, which commonly leads to diarrhea, especially early in treatment. Constipation is not the typical dominant GI effect, and saying there are no GI effects is incorrect. Nausea is also a frequent early side effect, but the option highlighting diarrhea reflects a common GI reaction with sertraline.

7. For pediatric antidepressant follow-up, how often should follow-up occur during the first four weeks after starting an antidepressant?

- A. Daily
- B. Weekly**
- C. Biweekly
- D. Monthly

The main idea here is that early after starting an antidepressant in kids and teens, close and frequent follow-up is essential. The first four weeks are a period when you closely watch for both safety and initial response: some patients may experience activating or activating-like side effects, sleep or appetite changes, or mood shifts, and the risk of emergent suicidality is a critical concern that needs regular assessment. Weekly contact lets the clinician check how the patient is tolerating the medication, confirm that doses are being taken as prescribed, and decide promptly whether any dose adjustments are needed to improve effectiveness or reduce adverse effects. Daily follow-up isn't typically required and can be impractical, while biweekly or monthly check-ins in this early window could miss important early signals of adverse effects or lack of response. Therefore, weekly follow-ups best support safety and the initial response during the first four weeks.

8. What is the next treatment option after suboptimal response (<20% symptom improvement) or intolerance following 4-8 weeks of first-line antidepressant therapy?

- A. Switch to an alternative antidepressant in the same or different class (SSRI, SNRI, bupropion, or mirtazapine) ± psychotherapy**
- B. Discontinue treatment and consider non-pharmacologic therapy
- C. Augment with a 2nd-generation antipsychotic
- D. Maintain the current treatment and reassess in 2-4 weeks

When a first-line antidepressant has been given at an adequate dose for 4–8 weeks and there is only minimal improvement (less than about 20%) or the patient cannot tolerate it, the next step is to switch to another antidepressant, ideally with a different mechanism, and consider adding psychotherapy. Trying a different medication leverages other neurochemical targets, increasing the chance of a meaningful response. You can switch within the same class or to a different class (for example, from SSRI to SNRI, bupropion, or mirtazapine), guided by tolerability and symptom profile. Continuing the same drug without benefit is unlikely to help, and simply stopping treatment without a plan isn't appropriate. Augmentation with a second-generation antipsychotic is a valid option in some cases, but it's typically considered after an inadequate response to an initial switch or in partial responders, not as the default first move after a single failed trial.

9. Which of the following is not a DSM-5 symptom criterion for major depressive disorder?

- A. Depressed mood.
- B. Insomnia.
- C. Psychomotor agitation.

D. Euphoria.

Euphoria is not a symptom used to diagnose major depressive disorder. In MDD, the DSM-5 criteria require at least five symptoms that occur during the same two-week period, represent a change from previous functioning, and cause distress or impairment. At least one of the symptoms must be depressed mood or loss of interest (anhedonia). Other common symptoms include insomnia or hypersomnia, psychomotor agitation or retardation, fatigue, feelings of worthlessness or excessive guilt, trouble concentrating, and recurrent thoughts of death. Euphoria—a notably elevated or overly happy mood—is characteristic of mania or hypomania and points toward bipolar spectrum disorders rather than major depressive disorder.

10. Which of the following is NOT a symptom of antidepressant withdrawal syndrome?

- A. Flu-like symptoms
- B. Insomnia
- C. Nausea

D. Weight gain

When antidepressants are stopped abruptly, the brain reacts to the sudden drop in serotonin, norepinephrine, and other neurotransmitters, leading to a withdrawal syndrome that unfolds with physical and psychological symptoms. The most typical signs reflect rebound autonomic and GI responses: flu like malaise, insomnia or sleep disturbances, nausea, dizziness, and sometimes headaches or sweating. You may also notice mood swings, irritability, anxiety, or heightened sensitivity to stimuli. Weight gain, on the other hand, does not fit this withdrawal pattern. It is more commonly a side effect that can develop with ongoing antidepressant use or long-term metabolic changes, rather than a direct withdrawal symptom. So, weight gain isn't part of the typical withdrawal picture. If weight changes occur during discontinuation, they're not considered a defining withdrawal feature and can be influenced by several other factors.

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

<https://ip8depressiontherapeutics.examzify.com>

We wish you the very best on your exam journey. You've got this!

SAMPLE